NPIL acquires inhalation anaesthetic business from UK based RhodiaNicholas Piramal India Ltd.
(NPIL) has acquired the global Inhalation Anaesthetics (IA) business of the UK based Rhodia Organique Fine Limited for a consideration of USD 14 million, informed a press release.

Ranbaxy gains US FDA approval for fluoxetine capsules
RANBAXY Laboratories Limited (RLL) announced that the company has received approval from the US Food and Drug Administration to manufacture and market Fluoxetine 40mg capsules.

Cadila to focus on cardiovascular, gastroenteritis segments
Cadila Pharmaceuticals Ltd plans to focus on cardiovascular and gastroenteritis segments to give its business a further boost.

Lupin appoints Indrajit Banerjee as President - Finance and Planning
Lupin Ltd announced the joining of Indrajit Banerjee as President (Finance and Planning. Banerjee is a chartered accountant with over two decades of experience in companies like Indal and Lucent Technologies. In his earlier stint in Lupin Banerjee was Head of Finance.

Global R&D alliances to become trend setters in India
Although it took one year for R&D alliances like that of the Ranbaxy-GSK collaboration to happen, finally it looks like the Indian pharmaceutical market is set to witness changes the way global companies perceive India as an R&D destination.